Literature DB >> 7065143

Splanchnic hemodynamics in portal-hypertensive rats: measurement with gamma-labeled microspheres.

R J Groszmann, J Vorobioff, E Riley.   

Abstract

A method to quantitate hepatic arterial flow (HA), portal venous flow (PBF), and blood flow through portal-systemic shunts (ShBF) in portal-hypertensive rats is described. This method relies on the injection of two differently radiolabeled microspheres (15 micrometers) into the left ventricle and spleen. To evaluate the usefulness of this technique, studies were performed on normal, cirrhotic, and portal vein-ligated rats anesthetized with ketamine. With this method, PBF is calculated indirectly from the sums of the blood flow of the splanchnic organs that drain into the portal vein. In the portal-hypertensive animals with portal-systemic shunting, this technique allows for the determination of PBF perfusing the liver [hepatic fraction of portal flow (HFP)] and PBF escaping through portal-systemic shunts (ShBF). The portal vein-ligated rats have higher HA flow (0.68 +/- 0.08 ml . min-1 . g-1) and lower HFP (0.08 +/- 0.01 ml . min-1 . g-1) than either the cirrhotic (HA: 0.27 +/- 0.03 ml . min-1 . g-1, P less than 0.01; HFP: 1.20 +/- 0.20 ml . min-1 . g-1, P less than 0.01) or the normal rat (HA: 0.29 +/- 0.06 ml . min-1 . g-1, P less than 0.01; HFP: 1.39 +/- 0.16 ml . min-1 . g-1, P less than 0.01). No significant difference was found between the cirrhotic and normal rats. The ShBF was higher in the portal vein-ligated rats (21.4 +/- 2.8 ml/min) than in the cirrhotic (4.6 +/- 2.5 ml/min, P less than 0.001) or normal rats (0.03 +/- 0.005 ml/min, P less than 0.01). The difference between the cirrhotic and normal animals was also significant (P less than 0.05). This is a simple, rapid, and reliable technique that allows for the quantitation of splanchnic hemodynamics in experimental models with portal hypertension.

Entities:  

Mesh:

Year:  1982        PMID: 7065143     DOI: 10.1152/ajpgi.1982.242.2.G156

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  21 in total

1.  Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension.

Authors:  M P Pizcueta; J M Piqué; J Bosch; B J Whittle; S Moncada
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

2.  Hepato-cardiovascular response and its regulation.

Authors:  Xiang-Nong Li; Irving S Benjamin; Barry Alexander
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

3.  Effect of a somatostatin analogue (SMS 201-995) on hemodynamics and glucagon secretion in cirrhotic rats.

Authors:  N Hori; T Okanoue; Y Sawa; T Mori; K Kashima
Journal:  Gastroenterol Jpn       Date:  1993-04

4.  Hepatic oxygen consumption, in vivo, in the rat.

Authors:  J E Bredfeldt; E M Riley; R J Groszmann
Journal:  Experientia       Date:  1983-07-15

5.  Hemodynamic studies in a parabiotic model of portal hypertension.

Authors:  E Sikuler; R J Groszmann
Journal:  Experientia       Date:  1985-10-15

6.  Location and function of intrahepatic shunts in anaesthetised rats.

Authors:  X Li; I S Benjamin; R Naftalin; B Alexander
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

7.  Temporary blood flow stasis with degradable starch microspheres (DSM) for liver metastases in a rat model.

Authors:  A D Flowerdew; H K Richards; I Taylor
Journal:  Gut       Date:  1987-10       Impact factor: 23.059

8.  Verapamil favorably influences hepatic microvascular exchange and function in rats with cirrhosis of the liver.

Authors:  J Reichen; M Le
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

9.  The lung in liver disease: old problem, new concepts.

Authors:  Michael B Fallon; Junlan Zhang
Journal:  Trans Am Clin Climatol Assoc       Date:  2013

10.  Intrahepatic portal occlusion by microspheres: a new model of portal hypertension in the rat.

Authors:  V Jaffe; B Alexander; R T Mathie
Journal:  Gut       Date:  1994-06       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.